OBJECTIVE: To evaluate adrenal and ovarian steroidogenesis before and after long-term treatment with @entity2449 in @entity1 with @entity3610 ( @entity3610 ). DESIGN AND METHODS: Twenty-four @entity1 with @entity3610 were evaluated before and after treatment (27+/-4 weeks) with @entity2449 (1000 mg/day) using adrenocorticotrophin (ACTH), @entity1176 analogue and oral @entity413 tolerance (oGTT) tests. For statistical evaluation, ANOVA and Wilcoxon's test were used. RESULTS: In 58% of the @entity1 a significant improvement in menstrual cyclicity was observed. No significant change in basal @entity134 levels was found. After ACTH stimulation, a significant decrease in the activity of @entity1816 dehydrogenase in C(21) @entity230 (P<0.05) and in @entity19674 dehydrogenase (P<0.01) was observed, as was an increase in the activity of C17,20-lyase in the Delta(4) pathway (P<0.01). A significant growth in the @entity2494 ( @entity2494 )/ @entity9027 ratio (P<0.05) was detected. With regard to ovarian steroidogenesis, a significant decrease in the stimulated levels of @entity251 (P<0.05), index of free @entity251 (P<0.01), LH (P<0.05) and @entity53 (P<0.01), and an increase in the levels of @entity46009 (P<0.05) were detected. In the indices of ovarian enzyme activities, we observed a significant decrease in 3 beta-hydroxysteroid dehydrogenase in @entity8030 @entity230 (P<0.01), in C17,20-lyase in the Delta 5 pathway (P<0.01), in 17 beta-hydroxysteroid dehydrogenase (P<0.05) and in aromatase. In @entity413 metabolism, a tendency towards reduction in the homeostasis model assessment (HOMA)-R (for insulin resistance) and HOMA-F (for beta cell function) was detected. In addition, an increase in the levels of C peptide during oGTT was observed (P<0.01). CONCLUSIONS: Long-term @entity2449 treatment reduced various @entity134 enzymatic activities both in the ovary and the adrenal glands, without apparent changes in basal @entity134 levels and in insulin sensitivity.

The effects of long-term @entity2449 treatment on adrenal and ovarian steroidogenesis in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['women'] @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome', 'PCOS'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity46009 :: ('MESH:D006907', 'Chemical') :: ['17-hydroxypregnenolone'] @entity19674 :: ('CHEBI:35343', 'Chemical') :: ['17 beta-hydroxysteroid'] @entity1816 :: ('CHEBI:36836', 'Chemical') :: ['3 beta-hydroxysteroid'] @entity2494 :: ('MESH:D003687', 'Chemical') :: ['DHEA', 'dehydroepiandrosterone'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['oestradiol'] @entity8030 :: ('79718', 'Gene') :: ['C21'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1176 :: ('MESH:D007987', 'Chemical') :: ['GnRH'] @entity9027 :: ('MESH:D019314', 'Chemical') :: ['DHEA-sulfate'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity3610 :: (MESH:D011085,Disease) :: ['polycystic ovary syndrome']
